Neogen Corp NEOG
We take great care to ensure that the data presented and summarized in this overview for NEOGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NEOG
View all-
Black Rock Inc. New York, NY25MShares$160 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$153 Million0.0% of portfolio
-
Ing Groep Nv14.1MShares$89.8 Million0.45% of portfolio
-
Clarkston Capital Partners, LLC Bloomfield Hills, MI11.7MShares$74.7 Million1.47% of portfolio
-
Gates Capital Management, Inc. New York, NY10.9MShares$69.7 Million1.33% of portfolio
-
State Street Corp Boston, MA8.75MShares$55.9 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.03MShares$51.3 Million0.01% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A67.82MShares$50 Million0.06% of portfolio
-
Bamco Inc New York, NY6.85MShares$43.8 Million0.11% of portfolio
-
William Blair Investment Management, LLC Chicago, IL5.91MShares$37.7 Million0.09% of portfolio
Latest Institutional Activity in NEOG
Top Purchases
Top Sells
About NEOG
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Insider Transactions at NEOG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 03
2025
|
Mikheal Nassif CEO |
BUY
Open market or private purchase
|
Indirect |
177
+26.34%
|
$1,062
$6.25 P/Share
|
|
Nov 03
2025
|
Richard Bryan Riggsbee CFO |
BUY
Grant, award, or other acquisition
|
Direct |
178,855
+50.0%
|
$1,073,130
$6.29 P/Share
|
|
Oct 27
2025
|
James C Borel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,802
+1.95%
|
$22,812
$6.19 P/Share
|
|
Oct 27
2025
|
Ronald D Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+8.7%
|
$10,662
$6.19 P/Share
|
|
Oct 27
2025
|
Jeffrey D Capello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,802
+5.68%
|
$22,812
$6.19 P/Share
|
|
Oct 27
2025
|
Aashima Gupta Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+6.01%
|
$10,662
$6.19 P/Share
|
|
Oct 27
2025
|
Rafael A Rodriguez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+7.86%
|
$10,662
$6.19 P/Share
|
|
Oct 27
2025
|
James P Tobin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+3.94%
|
$10,662
$6.19 P/Share
|
|
Oct 27
2025
|
Catherine E Woteki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+8.5%
|
$10,662
$6.19 P/Share
|
|
Oct 27
2025
|
Amy M Rocklin Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,085
-3.51%
|
$12,510
$6.19 P/Share
|
|
Oct 27
2025
|
Amy M Rocklin Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,474
+13.77%
|
$56,844
$6.19 P/Share
|
|
Oct 27
2025
|
David H. Naemura Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,261
-5.0%
|
$25,566
$6.19 P/Share
|
|
Oct 27
2025
|
David H. Naemura Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,504
+15.38%
|
$93,024
$6.19 P/Share
|
|
Oct 27
2025
|
Douglas Edward Jones Former COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,481
-3.34%
|
$20,886
$6.19 P/Share
|
|
Oct 27
2025
|
Douglas Edward Jones Former COO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,504
+12.93%
|
$93,024
$6.19 P/Share
|
|
Oct 27
2025
|
John Edward Adent Former CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,527
-2.29%
|
$51,162
$6.19 P/Share
|
|
Oct 27
2025
|
John Edward Adent Former CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,759
+9.45%
|
$232,554
$6.19 P/Share
|
|
Oct 27
2025
|
William T Boehm Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,553
+6.9%
|
$21,318
$6.07 P/Share
|
|
Oct 24
2025
|
Avi Pelossof Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,386
+50.0%
|
$116,316
$6.19 P/Share
|
|
Oct 23
2025
|
Catherine E Woteki Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,769
+36.04%
|
$118,614
$6.07 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.46M shares |
|---|---|
| Exercise of conversion of derivative security | 273K shares |
| Open market or private purchase | 190K shares |
| Payment of exercise price or tax liability | 59.8K shares |
|---|